News & Updates

Adjuvant treatment with metformin does not improve outcomes in most patients with early breast cancer in a phase III study, suggesting that metformin should not be used as a breast cancer treatment in these patients.

In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) who respond to first-line induction therapy with panitumumab plus fluorouracil, folinic acid and oxaliplatin (FOLFOX), maintenance panitumumab plus fluorouracil and folinic acid (FU/FA) significantly improves progression-free survival (PFS) vs FU/FA alone, results of the PANAMA trial have shown.

A novel combination of celecoxib and Myrtol for recurrent appendiceal mucinous neoplasma (AMN) with extensive peritoneal dissemination is well tolerated and appears to extend progression-free (PFS) and overall survival (OS) in patients, a recent study has found.

Magnetic resonance imaging (MRI)-targeted biopsy misses of clinically significant cancers seldom occur, but such rare cases are mostly caused by errors in lesion targeting, which underscores the importance of accurate coregistration and targeting when using software-based fusion platforms, according to a study. Moreover, some patients harbor MRI-invisible lesions, which cannot be targeted by MRI platforms.